ClinVar Miner

Submissions for variant NM_001114753.3(ENG):c.923C>A (p.Ala308Asp)

dbSNP: rs1482440395
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
NIHR Bioresource Rare Diseases, University of Cambridge RCV001263079 SCV001441159 likely pathogenic Telangiectasia, hereditary hemorrhagic, type 1 2018-01-01 criteria provided, single submitter research PS3+PM2+PP4+PP5
Invitae RCV001880054 SCV002303014 pathogenic Hereditary hemorrhagic telangiectasia 2023-10-04 criteria provided, single submitter clinical testing This sequence change replaces alanine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 308 of the ENG protein (p.Ala308Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of hereditary hemorrhagic telangiectasia (PMID: 16690726, 16752392, 22991266, 32573726). ClinVar contains an entry for this variant (Variation ID: 983206). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ENG protein function. Experimental studies have shown that this missense change affects ENG function (PMID: 22022569). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV002375316 SCV002686804 pathogenic Cardiovascular phenotype 2017-07-11 criteria provided, single submitter clinical testing The p.A308D pathogenic mutation (also known as c.923C>A), located in coding exon 7 of the ENG gene, results from a C to A substitution at nucleotide position 923. The alanine at codon 308 is replaced by aspartic acid, an amino acid with dissimilar properties. This mutation was identified in an individual with hereditary hemorrhagic telangiectasia (HHT) and a brain arteriovenous malformation (Nishida T et al. Am. J. Med. Genet. A, 2012 Nov;158A:2829-34). In two unrelated HHT families, this mutation segregated with disease (Bossler AD et al. Hum. Mutat., 2006 Jul;27:667-75); Prigoda NL et al. J. Med. Genet., 2006 Sep;43:722-8). An in vitro functional study found this mutation resulted in retention and mislocalization of the ENG protein to the endoplasmic reticulum instead of the plamsa membrane (Ali BR et al. PLoS ONE, 2011 Oct;6:e26206). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.